GSK Commits Over $800 Million to Montgomery County Expansion

GSK PLC (NYSE: GSK) announced an $800M investment to expand its Pennsylvania biopharmaceutical operations, creating 300 jobs. The company offers a 3.8% dividend yield with a 39% payout ratio, and its stock is fairly valued at $46.50. GSK has a GF Score of 77, indicating solid financial health and profitability.

GSK is advancing a subcutaneous version of its drug Jemperli, using Alteogen's ALT-B4, into clinical trials starting November. The Phase 1b/3 trial will enroll 380 patients with advanced endometrial cancer. GSK licensed ALT-B4 from Alteogen in January 2026 for USD 285 million in potential milestones. Jemperli generated GBP 861 million in 2025 sales. Alteogen's ALT-B4 is also used in MSD's Keytruda SC, which generated USD 463 million in Q2 2026.

GSK plans to invest over $800M to expand its operations in Upper Merion Township, Pennsylvania, creating 300 new jobs and retaining 4,500 existing ones. The expansion, set to begin in 2027, will establish a biopharmaceutical innovation and manufacturing hub. This is GSK's second major expansion in Pennsylvania since October 2024, totaling nearly $1.7B in investments. The company will receive tax benefits through state programs.

GSK (GSK) plans to invest over $800M in Pennsylvania to build a biologics manufacturing facility, R&D pilot plant, and quality control lab, creating 300 jobs. The company offers a 3.81% dividend yield, a GF Value of $45.29, and a GF Score of 77. Institutional interest is mixed, with 15 gurus holding shares.

GSK plans to invest over $800 million in a biopharma hub in Pennsylvania, creating 300 jobs. The state announced the investment, which is expected to boost the local economy and the company's operations.

GSK plans to invest over $800M to expand operations in Montgomery County, Pennsylvania, adding 300 jobs over five years. The company already employs 4,500 full-time workers in the state.